4basebio raises £15M to scale synthetic DNA push
What's the deal? Cambridge-based life sciences company 4basebioDealroom has a profile for this one. Try Dealroom → has raised £15 million in gross proceeds through a placing of 2.6 million shares at 515 pence each. The price represents an 8.4% discount to the stock's closing price on October 14. It also aims to raise a further £500,000 via a retail offer.
Who's backing it? 2invest AGDealroom has a profile for this one. Try Dealroom →, with which 4basebio holds a fully drawn £25 million loan facility, agreed to subscribe for 194,174 shares for £1 million. It also took 776,699 shares for £4 million, settled by cutting the outstanding loan balance to €21.1 million and extending the loan's maturity by two years to October 2030.
Certain directors and officers subscribed for 54,366 shares, worth £300,000.
What's the money for? Proceeds will support commercial development, complete the fit-out of its Q-ArcDealroom has a profile for this one. Try Dealroom → commercial facility, fund R&D, and cover working capital. The raise gives 4basebio cash runway into the second half of 2028.
What's the endgame? The company makes synthetic DNA for research and clinical applications. Chief executive officer Amy Walker said the raise will "provide the company important resources to expand services and offerings to meet the growing demands of the genomic medicines landscape."
Why now? Walker pointed to "steady interest and adoption in synthetic DNA" that has grown its client base and pipeline. Its expansion of GMP-grade services for clinical trials is "fuelling the acceleration in client acquisition and revenue generation," she said.
The signal: At £15 million, this is a sizeable top-up for a listed life sciences firm — though still modest against the broader funding landscape. The structure, part cash and part debt-for-equity, signals 2invest's deepening commitment as both lender and shareholder.
Read more: sa.marketscreener.com
